Quarterly report (Form 10-Q)
Edwards Lifesciences 10-Q for Quarter ended Sep 30, 2026
Filing excerpt
We recognized an expense of $2.0 million related to severance associated with realignment initiatives and $8.7 million related to the termination of certain contracts associated with our acquisitions during the three and nine months ended September 30, 2026.